

Kick-off Meeting

07th-08th February 2019

Hotel Steigenberger am Kanzleramt
Ella-Trebbe-Str. 5 - 10557 Berlin, Germany

DAY I - 07th FEBRUARY 2019 (Meeting room: Salon 5)

10.30-11.00 **Registration and welcome coffee**

11.00-11.15 **Official opening by the dean of the faculty**

Axel Radlach Pries - Charité - Universitätsmedizin Berlin, Germany

11.15-12.45 **Welcome & introduction (incl. IPR management)**

Petra Reinke - Charité - Universitätsmedizin Berlin, Germany

12.45-13.00 **Financial and administrative management**

Gabriella Dessole - Innovation Acta S.R.L, Italy

13.00-14.00 *Lunch*

WP1 - Next-generation Treg development platform

Chair: Ignacio Anegon - Centre Hospitalier Universitaire de Nantes, France

14.00-14.40 **Task 1.1 Enhanced target antigen specificity by CAR Treg approach**

Subproject 1: Allospecific CAR-Treg (Final Milestone: approved GMP manufacturing process)

& Task 1.9 Exploration of the feasibility of using allogeneic off-the-shelf Treg products

(Final Milestone: ready for transfer of the most promising candidate into GMP manufacturing process)

Ignacio Anegon - Centre Hospitalier Universitaire de Nantes, France

14.40-15.10 **Task 1.1 Enhanced target antigen specificity by CAR Treg approach**

Subproject 2: Tissue(Autoantigen)-specific CAR-Treg

(Final Milestone: approved GMP manufacturing process)

Elmar Jäckel - Medizinische Hochschule Hannover, Germany

15.10-15.50 **Task 1.2 Enhanced target antigen specificity by TCR Treg approach – Cas9 specific TCR-Treg as a role model**

(Final Milestone: ready for transfer into GMP manufacturing process for generating Cas9-spec. TCR Treg)

& Task 1.7 Enhanced engraftment of Treg by inducing resistance to immune-suppressive drugs using CRISPR/Cas9 technology & by enabling to deliver locally IL-2

Subproject 2: Enabling Treg to secrete autocrine IL-2 in vivo

(Final Milestone: ready for transfer into GMP manufacturing process)

Michael Schmück-Henneresse - Charité - Universitätsmedizin Berlin, Germany


15.50-16.30 *Coffee break*



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 825392.

Organization and Graphic project by:






Kick-off Meeting

07th-08th February 2019

Hotel Steigenberger am Kanzleramt
Ella-Trebbe-Str. 5 - 10557 Berlin, Germany

- 16.30-17.10** **Task 1.4 Enhanced stability of Treg products to inflammatory triggers by CRISPR/Cas9 mediated knock-down switch points (SPR-Treg)**
(Final Milestone: selection of the most promising SPR-Treg product candidate for further development to GMP-grade product)
& Task 1.7 Enhanced engraftment of Treg by inducing resistance to immune-suppressive drugs using CRISPR/Cas9 technology & by enabling to deliver locally IL-2
Subproject 1: Resistance to Immunosuppressive drugs by CRISPR/Cas9 technology
(Final Milestone: approved GMP manufacturing process for generating these next-generation Treg)
Dimitrios Laurin Wagner - Charité - Universitätsmedizin Berlin, Germany
- 17.10-17.40** **Task 1.3 Enhanced stability of Treg products by epigenetic modification**
(Final Milestone: ready for transfer into GMP manufacturing process for generating epigenetically stabilized Treg)
& Task 2.3 Molecular Signature (RNA seq, TCR seq, Methylation) of Treg products
(Final Milestone: Molecular signature of all Treg candidates)
Julia K. Polansky-Biskup - Charité - Universitätsmedizin Berlin, Germany
- 17.40-18.00** **Task 1.5 Generation of stable regulatory T cell by programming mitochondrial morphology & cellular metabolism**
(Final Milestone: ready for transfer of the most promising candidate into GMP manufacturing process)
Christina Iwert and Kerstin Mühle - Charité - Universitätsmedizin Berlin, Germany
- 18.00-18.30** **Task 1.6 Exploring CD8+ Treg as an alternative and/or complementary to CD4+ Treg**
(Final Milestone: approved GMP manufacturing process for generating these CD8+ Treg)
Carole Guillonnet - Centre Hospitalier Universitaire de Nantes, France
- 18.30-19.00** **Task 1.8 Development of virus-free gene transfer into Treg**
(Final Milestone: 1-2 fully validated non-viral gene transfer methods applicable for Treg)
Tristan Thwaites and Hanna Milewicz - Cell and Gene Therapy Catapult Limited, UK
- 19.30** *Networking dinner* at Restaurant Fashion (Hotel Steigenberger am Kanzleramt)





Kick-off Meeting

07th-08th February 2019

Hotel Steigenberger am Kanzleramt
Ella-Trebbe-Str. 5 - 10557 Berlin, Germany

DAY II - 08th FEBRUARY 2019 (Meeting room: Salon 5)

WP2 - Next-generation Treg product characterisation platform

Chair: Markus Templin - Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen, Germany

08.30-09.00 Task 2.1 Proteomics for characterisation of Treg products

Subproject 1: Targeted proteomics approaches: DigiWest and Luminex

(Final Milestone: In-depth proteomics analysis of all preselected Treg candidates)

Markus Templin - Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen, Germany

09.00-09.20 Task 2.1 Proteomics for characterisation of Treg products

Subproject 2: Unbiased proteomics approach

Final Milestone: In-depth proteomics analysis of all preselected Treg candidates)

Oliver Klein - Charité - Universitätsmedizin Berlin, Germany

09.20-09.40 Task 2.2 Multiparameter Flow/Mass Cytometry for characterization of Treg products

Final Milestone: In-depth cytometric analysis of all Treg candidates)

Mathias Streitz - Charité - Universitätsmedizin Berlin, Germany

WP3 - Next-generation test platform for new *in vivo* & *in vitro* preclinical models

Chair: Joanna Hester - University of Oxford, UK

09.40-10.10 Task 3.1 *In vivo* (modified "humanized" rodents models) preclinical (disease) models

(Final Milestone: Proof-of-Concept by *in vivo* analysis of all preselected Treg candidates)

Fadi Issa - University of Oxford, UK

10.10-10.40 Task 3.2 *In vitro* (organ/human-on-the-chip technology) preclinical (disease) models

(Final Milestone: Proof-of-Concept by *in vitro* analysis of all preselected Treg candidates)

Uwe Marx - TlssUse GmbH, Germany


10.40-11.10 *Coffee break*



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 825392.

Organization and Graphic project by:





Kick-off Meeting

07th-08th February 2019

Hotel Steigenberger am Kanzleramt
Ella-Trebbe-Str. 5 - 10557 Berlin, Germany

WP4 - Clinical Trial platform to prove the next generation Treg approaches

Chair: Tim Schmidt - TxCell/Sangamo Therapeutics, France

combined with:

WP 5 - Biomarker platform to monitor therapy response to next-generation Treg approaches

Chair: Hans Dieter Volk - Charité - Universitätsmedizin Berlin, Germany

11.10-11.50 Task 4.1 Improvement of in vivo engraftment of adoptively transferred Treg by specific conditioning of the Recipients

Clinical study n° 2: "ProTreg Trial - A Phase I/IIa single dose study to investigate the safety and tolerability of tTregs as an adjunctive therapy in CD kidney recipients following anti-thymocyte (ATG) induction therapy"

(Final Milestone: Clinical Proof-of-Concept of the combination T-cell depletion + Treg)

& Task 5.1 Validation and performance of biomarker studies for safety, PK/PD, mode-of-action

(Final Milestone: Summary & conclusion regarding PK/PD, safety, putative surrogate markers, mode-of-action from biomarker analyses of the clinical trial)

Petra Reinke and Hans Dieter Volk - Charité - Universitätsmedizin Berlin, Germany

11.50-12.30 Task 4.1 Improvement of in vivo engraftment of adoptively transferred Treg by specific conditioning of the Recipients

Clinical study n° 3: "The TWO Study: Transplantation Without Over-immunosuppression"

(Final Milestone: Clinical Proof-of-Concept of the combination T-cell depletion + Treg)

& Task 5.1 Validation and performance of biomarker studies for safety, PK/PD, mode-of-action

(Final Milestone: Summary & conclusion regarding PK/PD, safety, putative surrogate markers, mode-of-action from biomarker analyses of the clinical trial)

Joanna Hester - University of Oxford, UK

12.30-12.50 Task 4.2 FIH clinical trials of the next-generation Treg products

Clinical study n° 1: "The TacRes Trial - First-in-human (FIH) phase I trial for safety assessment of CRISPR/Cas9 permitted Calcineurin inhibitor (CNI) resistant (FKBP-KO) autologous tTreg application in CD renal transplant recipients"

(Final Milestone: FIH clinical trial of next-generation Treg product to prove safety and hints of efficacy)

Petra Reinke - Charité - Universitätsmedizin Berlin, Germany

12.50-13.10 Task 4.2 FIH clinical trials of the next-generation Treg products


Clinical study n° 4: "The RESHAPE Study CD8+Treg Trial ("Eight-Treg")"

(Final Milestone: FIH clinical trial of next-generation Treg product to prove safety and hints of efficacy)

Carole Guillonneau - Centre Hospitalier Universitaire de Nantes, France

13.10-14.15 *Lunch*





Kick-off Meeting

07th-08th February 2019

Hotel Steigenberger am Kanzleramt
Ella-Trebbe-Str. 5 - 10557 Berlin, Germany

WP6 - Clinical Development research and early HTA for supporting exploitation strategies & business models for next-generation Treg approaches

Chair: Mohamed Abou El-Enein - Charité - Universitätsmedizin Berlin, Germany

14.15-14:45 Task 6.1 Clinical Development Research

Mohamed Abou El-Enein - Charité - Universitätsmedizin Berlin, Germany

14.45-15.15 Task 6.2 Early Health Technology Assessment

Tim Schmidt - TxCell/Sangamo Therapeutics, France

WP7 - Dissemination, Exploitation, Communication

Chair: Gabriella Dessole - Innovation Acta S.R.L, Italy

15.15-15.40 Dissemination, project website, development and implementation of an exploitation plan

Gabriella Dessole - Innovation Acta S.R.L, Italy

15.40-16.15 *Coffee break* & Consultation round Project Ethics Committee/External Advisory Board

16.15-16.45 Statement of the Project Ethics Committee (reserved to Project Ethics Committee members)

16.45-17.15 Statement of the External Advisory Board (reserved to External Advisory Board members)

Recapitulation & discussion

